Skip to main content
Top
Published in: Journal of Translational Medicine 1/2015

Open Access 01-12-2015 | Research

Downregulation of microRNA-409-3p promotes aggressiveness and metastasis in colorectal cancer: an indication for personalized medicine

Authors: Mulin Liu, Aman Xu, Xiao Yuan, Qiao Zhang, Taotao Fang, Wenbin Wang, Chenglong Li

Published in: Journal of Translational Medicine | Issue 1/2015

Login to get access

Abstract

Background

MicroRNAs play an ess ential role in colorectal cancer development and progression. Aberrant miR-409-3p expression has been reported in several cancers. However, the clinical significance and functions of miR-409-3p in human CRC were not entirely clear.

Methods

miR-409-3p expression levels were determined in 45 pairs of primary CRC and their corresponding adjacent non-tumor tissues by qPCR. The effects of ectopic expression of miR-409-3p on CRC cells proliferation, wound healing, metastasis were investigated by CCK-8, transwell assay and peritoneal spreading nude mice model.

Results

Statistical analysis of clinical cases revealed that low miR-409-3p expression had inclinations towards lager tumor size and local invasion. Ectopic expression of miRNA mimics suggested that miR-409-3p could inhibits the abilities of proliferation, wound healing, metastasis and invasion in CRC cells. Notably, we found the NLK could be a potential target of miR-409-3p.

Conclusion

Our results suggest that miR-409-3p functions as a tumor suppressor by inhibiting the development and metastasis of CRC, suggesting that miR-409-3p is expected to become a new diagnostic marker and a new target of the treatment of CRC.
Literature
1.
go back to reference Center MM, Jemal A, Ward E (2009) International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 18:1688–1694PubMedCrossRef Center MM, Jemal A, Ward E (2009) International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 18:1688–1694PubMedCrossRef
2.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef
3.
4.
go back to reference O’Hara SP, Mott JL, Splinter PL, Gores GJ, LaRusso NF (2009) MicroRNAs: key modulators of posttranscriptional gene expression. Gastroenterology 136:17–25PubMedCentralPubMedCrossRef O’Hara SP, Mott JL, Splinter PL, Gores GJ, LaRusso NF (2009) MicroRNAs: key modulators of posttranscriptional gene expression. Gastroenterology 136:17–25PubMedCentralPubMedCrossRef
5.
6.
go back to reference Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M et al (2007) The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 67:1419–1423PubMedCrossRef Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M et al (2007) The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 67:1419–1423PubMedCrossRef
8.
go back to reference Zheng B, Liang L, Huang S, Zha R, Liu L, Jia D et al (2012) MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers. Oncogene 31:4509–4516PubMedCrossRef Zheng B, Liang L, Huang S, Zha R, Liu L, Jia D et al (2012) MicroRNA-409 suppresses tumour cell invasion and metastasis by directly targeting radixin in gastric cancers. Oncogene 31:4509–4516PubMedCrossRef
9.
go back to reference Li C, Nie H, Wang M, Su L, Li J, Yu B et al (2012) MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting PHF10 in gastric cancer. Cancer Lett 320:189–197PubMedCrossRef Li C, Nie H, Wang M, Su L, Li J, Yu B et al (2012) MicroRNA-409-3p regulates cell proliferation and apoptosis by targeting PHF10 in gastric cancer. Cancer Lett 320:189–197PubMedCrossRef
10.
go back to reference Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE et al (2014) Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. Oncogene 34(21):2690–2699PubMedCrossRef Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE et al (2014) Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. Oncogene 34(21):2690–2699PubMedCrossRef
11.
go back to reference Xu X, Chen H, Lin Y, Hu Z, Mao Y, Wu J et al (2013) MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met. Mol Cells 36:62–68PubMedCentralPubMedCrossRef Xu X, Chen H, Lin Y, Hu Z, Mao Y, Wu J et al (2013) MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met. Mol Cells 36:62–68PubMedCentralPubMedCrossRef
12.
go back to reference Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X et al (2015) A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer 136:152–161PubMedCrossRef Wang S, Xiang J, Li Z, Lu S, Hu J, Gao X et al (2015) A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer 136:152–161PubMedCrossRef
14.
go back to reference Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. Cell 115:787–798PubMedCrossRef Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. Cell 115:787–798PubMedCrossRef
18.
go back to reference Breving K, Esquela-Kerscher A (2010) The complexities of microRNA regulation: mirandering around the rules. Int J Biochem Cell Biol 42:1316–1329PubMedCrossRef Breving K, Esquela-Kerscher A (2010) The complexities of microRNA regulation: mirandering around the rules. Int J Biochem Cell Biol 42:1316–1329PubMedCrossRef
19.
go back to reference Wan L, Zhu L, Xu J, Lu B, Yang Y, Liu F et al (2014) MicroRNA-409-3p functions as a tumor suppressor in human lung adenocarcinoma by targeting c-Met. Cell Physiol Biochem 34:1273–1290PubMedCrossRef Wan L, Zhu L, Xu J, Lu B, Yang Y, Liu F et al (2014) MicroRNA-409-3p functions as a tumor suppressor in human lung adenocarcinoma by targeting c-Met. Cell Physiol Biochem 34:1273–1290PubMedCrossRef
20.
go back to reference Brott BK, Pinsky BA, Erikson RL (1998) Nlk is a murine protein kinase related to Erk/MAP kinases and localized in the nucleus. Proc Natl Acad Sci USA 95:963–968PubMedCentralPubMedCrossRef Brott BK, Pinsky BA, Erikson RL (1998) Nlk is a murine protein kinase related to Erk/MAP kinases and localized in the nucleus. Proc Natl Acad Sci USA 95:963–968PubMedCentralPubMedCrossRef
21.
go back to reference Anastas JN, Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13:11–26PubMedCrossRef Anastas JN, Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13:11–26PubMedCrossRef
22.
go back to reference Zhang Y, Peng C, Wu G, Wang Y, Liu R, Yang S et al (2011) Expression of NLK and its potential effect in ovarian cancer chemotherapy. Int J Gynecol Cancer 21:1380–1387PubMedCrossRef Zhang Y, Peng C, Wu G, Wang Y, Liu R, Yang S et al (2011) Expression of NLK and its potential effect in ovarian cancer chemotherapy. Int J Gynecol Cancer 21:1380–1387PubMedCrossRef
23.
go back to reference Cui G, Li Z, Shao B, Zhao L, Zhou Y, Lu T et al (2011) Clinical and biological significance of nemo-like kinase expression in glioma. J Clin Neurosci 18:271–275PubMedCrossRef Cui G, Li Z, Shao B, Zhao L, Zhou Y, Lu T et al (2011) Clinical and biological significance of nemo-like kinase expression in glioma. J Clin Neurosci 18:271–275PubMedCrossRef
24.
go back to reference Emami KH, Brown LG, Pitts TE, Sun X, Vessella RL, Corey E (2009) Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate 69:1481–1492PubMedCentralPubMedCrossRef Emami KH, Brown LG, Pitts TE, Sun X, Vessella RL, Corey E (2009) Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate 69:1481–1492PubMedCentralPubMedCrossRef
25.
go back to reference Li M, Zhang S, Wang Z, Zhang B, Wu X, Weng H et al (2013) Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer. Tumour Biol 34:3995–4000PubMedCrossRef Li M, Zhang S, Wang Z, Zhang B, Wu X, Weng H et al (2013) Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer. Tumour Biol 34:3995–4000PubMedCrossRef
26.
go back to reference Jung KH, Kim JK, Noh JH, Eun JW, Bae HJ, Xie HJ et al (2010) Targeted disruption of nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J Cell Biochem 110:687–696PubMedCrossRef Jung KH, Kim JK, Noh JH, Eun JW, Bae HJ, Xie HJ et al (2010) Targeted disruption of nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J Cell Biochem 110:687–696PubMedCrossRef
27.
go back to reference Dong JR, Guo N, Zhao JP, Liu PD, Feng HH, Li Y (2013) Inhibition of nemo-like kinase increases taxol sensitivity in laryngeal cancer. Asian Pac J Cancer Prev 14:7137–7141PubMedCrossRef Dong JR, Guo N, Zhao JP, Liu PD, Feng HH, Li Y (2013) Inhibition of nemo-like kinase increases taxol sensitivity in laryngeal cancer. Asian Pac J Cancer Prev 14:7137–7141PubMedCrossRef
28.
go back to reference Chen J, Han Y, Zhao X, Yang M, Liu B, Xi X et al (2015) Nemolike kinase expression predicts poor survival in colorectal cancer. Mol Med Rep 11:1181–1187PubMed Chen J, Han Y, Zhao X, Yang M, Liu B, Xi X et al (2015) Nemolike kinase expression predicts poor survival in colorectal cancer. Mol Med Rep 11:1181–1187PubMed
29.
go back to reference Kim HA, Koo BK, Cho JH, Kim YY, Seong J, Chang HJ et al (2012) Notch1 counteracts WNT/beta-catenin signaling through chromatin modification in colorectal cancer. J Clin Invest 122:3248–3259PubMedCentralPubMedCrossRef Kim HA, Koo BK, Cho JH, Kim YY, Seong J, Chang HJ et al (2012) Notch1 counteracts WNT/beta-catenin signaling through chromatin modification in colorectal cancer. J Clin Invest 122:3248–3259PubMedCentralPubMedCrossRef
31.
go back to reference Manceau G, Imbeaud S, Thiebaut R, Liebaert F, Fontaine K, Rousseau F et al (2014) Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res 20:3338–3347PubMedCrossRef Manceau G, Imbeaud S, Thiebaut R, Liebaert F, Fontaine K, Rousseau F et al (2014) Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res 20:3338–3347PubMedCrossRef
32.
go back to reference Milosevic J, Pandit K, Magister M, Rabinovich E, Ellwanger DC, Yu G et al (2012) Profibrotic role of miR-154 in pulmonary fibrosis. Am J Respir Cell Mol Biol 47:879–887PubMedCentralPubMedCrossRef Milosevic J, Pandit K, Magister M, Rabinovich E, Ellwanger DC, Yu G et al (2012) Profibrotic role of miR-154 in pulmonary fibrosis. Am J Respir Cell Mol Biol 47:879–887PubMedCentralPubMedCrossRef
33.
go back to reference Tsai KW, Wu CW, Hu LY, Li SC, Liao YL, Lai CH et al (2011) Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer 129:2600–2610PubMedCrossRef Tsai KW, Wu CW, Hu LY, Li SC, Liao YL, Lai CH et al (2011) Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer 129:2600–2610PubMedCrossRef
Metadata
Title
Downregulation of microRNA-409-3p promotes aggressiveness and metastasis in colorectal cancer: an indication for personalized medicine
Authors
Mulin Liu
Aman Xu
Xiao Yuan
Qiao Zhang
Taotao Fang
Wenbin Wang
Chenglong Li
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2015
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-015-0533-x

Other articles of this Issue 1/2015

Journal of Translational Medicine 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.